12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Communications regarding the maintenance of domestic supply of essential drug products.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Incentives and programs to attract and support manufacturing activities in Canada	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.	Legislative Proposal, Bill or Resolution, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.	Regulation

  Subject matters in previous versions

  • Budget
  • Economic Development
  • Health
  • Industry
  • Intellectual Property
  • International Development
  • International Trade
  • Justice and Law Enforcement
  • Privacy and Access to Information
  • Research and Development
  • Science and Technology

Government Institutions

• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Oral communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Berkeley Vincent, President | No public offices held
• Dozie Amuzie, Head of JLABS Canada | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Monica Da Re, Senior Manager, Government Affairs & Policy | No public offices held

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Katherine Tsokas, Vice President Regulatory, Quality, Risk Management and Drug Safety | No public offices held

  Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

  • Jim Pimblett, Director, Government Affairs and Policy | Designated public offices held